Conferences
Conferences
Advertisement
Julian Chavarriaga, MDTesticular, Penile, and Rare Malignancies | April 12, 2024
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Read More
Marco Finati, MDProstate Cancer | April 9, 2024
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Guy Verhovsky, MDUrothelial Carcinoma | April 11, 2024
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Amanda Myers, MDNon-Muscle Invasive Urothelial Carcinoma | April 9, 2024
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Steven Canfield, MDLocalized | April 9, 2024
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Katy MarshallMuscle Invasive Urothelial Carcinoma | April 8, 2024
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
The UromigosThe Uromigos | April 8, 2024
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
The UromigosThe Uromigos | April 8, 2024
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
Zachary BessetteLocalized Renal Cell Carcinoma | April 8, 2024
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 8, 2024
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Zachary BessetteLocalized | April 9, 2024
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Zachary BessetteUpper Tract Urothelial Carcinoma | April 8, 2024
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 8, 2024
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
Emily MenendezLocalized | April 8, 2024
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Emily MenendezUpper Tract Urothelial Carcinoma | April 8, 2024
The nomogram is used preoperatively to determine the probability of nodal tropism.
Katy MarshallUrothelial Carcinoma | April 8, 2024
Researchers assessed recurrence rates, overall survival, and disease progression.
Katy MarshallUpper Tract Urothelial Carcinoma | April 8, 2024
Previous trials have revealed that neoadjuvant chemotherapy is an effective treatment path for patients with high-grade UTUC.
Katy MarshallTesticular, Penile, and Rare Malignancies | April 8, 2024
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Advertisement
Advertisement
Advertisement